RxSight Inc (RXST)
61.78
+2.14
(+3.60%)
USD |
NASDAQ |
May 03, 16:00
61.78
0.00 (0.00%)
After-Hours: 20:00
RxSight SG&A Expense (Quarterly): 21.16M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 21.16M |
September 30, 2023 | 19.14M |
June 30, 2023 | 18.24M |
March 31, 2023 | 16.26M |
December 31, 2022 | 15.73M |
September 30, 2022 | 14.93M |
June 30, 2022 | 14.39M |
March 31, 2022 | 13.62M |
Date | Value |
---|---|
December 31, 2021 | 11.62M |
September 30, 2021 | 9.076M |
June 30, 2021 | 6.502M |
March 31, 2021 | 5.611M |
December 31, 2020 | 4.403M |
September 30, 2020 | 3.825M |
June 30, 2020 | 3.249M |
March 31, 2020 | 3.698M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
3.249M
Minimum
Jun 2020
21.16M
Maximum
Dec 2023
11.34M
Average
12.62M
Median
SG&A Expense (Quarterly) Benchmarks
Abbott Laboratories | 2.959B |
Alphatec Holdings Inc | 104.12M |
AtriCure Inc | 72.34M |
Intuitive Surgical Inc | 491.50M |
iRhythm Technologies Inc | 100.11M |